This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Addressing Challenges to Optimal Diagnosis and Treatment of Invasive Fungal Infections

Addressing Challenges to Optimal Diagnosis and Treatment of Invasive Fungal Infections

Format

Webcast

Time to Complete

1 hour

Released

February 21, 2018

Expires

February 21, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CE for Nurses (0.50 pharmacology credits)
1.00 / CE for Pharmacists (0.10 CEUs)

Accredited Provider

Jointly provided by Global Education Group and Integrity Continuing Education

Commercial Supporter

Supported by an educational grant from Astellas Pharma US, Inc.

Program Description

Fungal infections are rampant throughout the world, causing an estimated one billion skin infections, more than 100 million mucosal infections, and approximately one million deaths per year. For most people, fungal infections are relatively minor, but some fungal infections are life-threatening. Those at greatest risk for life-threatening invasive fungal infections are people with weakened immune systems. As medicine advances, more people are being subjected to immunosuppression than ever before, causing an increase in invasive fungal infections (IFIs).

Hospital Medicine Summit (HMS) is an innovative, multi-topic educational initiative designed specifically for hospital-based healthcare providers (hospitalists, internal medicine physicians, physician assistants, nurse practitioners, pharmacists, and nurses). With significant changes occurring in the healthcare system, there is an increased demand on hospital-based healthcare providers to provide care that impacts patients not only in the acute setting, but as they transition back into the community and are managed in the chronic-care healthcare system.

Intended Audience

This educational initiative has been designed for hospital-based, multidisciplinary healthcare providers involved in the management of patients with IFIs.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify challenges in the diagnosis of common IFIs and recognize clinical circumstances that require empirical treatment
  • Review the emerging patterns and underlying mechanisms of fungal resistance
  • Describe current guideline recommendations for the treatment of IFIs

Conflict Of Interest Disclosure Policy

Integrity Continuing Education and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Global Education Group are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

John R. Perfect, MD
James B. Duke Professor of Medicine
Chief, Division of Infectious Diseases and International Health
Duke University Medical Center
Durham, NC

Dr. Perfect discloses the following:
Consultant: Astellas Pharma US, Inc., Cidara Therapeutics, Matinas BioPharma, Merck, Scynexis, Viamet Pharmaceuticals, Inc., Vical
Research: Amplyx Pharmaceuticals, Inc., Pfizer, Viamet Pharmaceuticals, Inc.

Planners and Managers Disclosures

The following planners and managers, Andrea Funk, Liddy Knight, Lindsay Borvansky, Ashley Marostica, RN, MSN, and Patima Tanapat, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CE for Nurses

Accreditation Statement

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

This educational activity for 1.00 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Designated for 0.50 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

Global Education Group designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number: 0530-9999-17-346-H01-P)

Activity Type: Knowledge

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Global Education Group, and Astellas Pharma US, Inc., do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Global Education Group, and Astellas Pharma US, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Instructions

There are no fees for participating and receiving CME credit for this activity. During the period of February 21, 2018 through February 21, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70%.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue